Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours
Copyright © 2018 Elsevier Ltd. All rights reserved..
Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms regarding their molecular biology, clinical behaviour, prognosis and response to therapy. Several attempts to establish robust predictive biomarkers have failed. Neither tissue markers nor blood borne ones have proven to be successful yet. Circulating tumour cells (CTCs) as "liquid biopsies" could provide prognostic information at the time a therapeutic decision needs to be made and could be an attractive tool for tumour monitoring throughout the treatment period. However, "liquid biopsies" are far from becoming the standard biomarker in NETs. Promising results have been presented over the last few years using a novel biomarker candidate, a multianalyte algorithm analysis PCR-based test (NETest). New technologies will open the field to different ways of approaching the biomarker conundrum in NETs. However, the complications derived from being a heterogeneous group of malignancies will remain with us forever. In summary, there is an unmet need to incorporate new biomarker candidates into clinical research trials to obtain a robust prospective validation under the most demanding scenario.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Cancer treatment reviews - 70(2018) vom: 15. Nov., Seite 209-222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barriuso, Jorge [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.11.2018 Date Revised 20.11.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ctrv.2018.09.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289283183 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289283183 | ||
| 003 | DE-627 | ||
| 005 | 20231225062219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2018.09.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0964.xml |
| 035 | |a (DE-627)NLM289283183 | ||
| 035 | |a (NLM)30292979 | ||
| 035 | |a (PII)S0305-7372(18)30162-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barriuso, Jorge |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2018 | ||
| 500 | |a Date Revised 20.11.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms regarding their molecular biology, clinical behaviour, prognosis and response to therapy. Several attempts to establish robust predictive biomarkers have failed. Neither tissue markers nor blood borne ones have proven to be successful yet. Circulating tumour cells (CTCs) as "liquid biopsies" could provide prognostic information at the time a therapeutic decision needs to be made and could be an attractive tool for tumour monitoring throughout the treatment period. However, "liquid biopsies" are far from becoming the standard biomarker in NETs. Promising results have been presented over the last few years using a novel biomarker candidate, a multianalyte algorithm analysis PCR-based test (NETest). New technologies will open the field to different ways of approaching the biomarker conundrum in NETs. However, the complications derived from being a heterogeneous group of malignancies will remain with us forever. In summary, there is an unmet need to incorporate new biomarker candidates into clinical research trials to obtain a robust prospective validation under the most demanding scenario | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Neuroendocrine tumours | |
| 650 | 4 | |a Peptide receptor radionuclide therapy | |
| 650 | 4 | |a Predictive biomarkers | |
| 650 | 4 | |a Somatostatin analogs | |
| 650 | 4 | |a Somatostatin receptors | |
| 650 | 4 | |a Telotristat ethyl | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Receptors, Peptide |2 NLM | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 650 | 7 | |a Somatostatin |2 NLM | |
| 650 | 7 | |a 51110-01-1 |2 NLM | |
| 700 | 1 | |a Custodio, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Afonso, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Astudillo, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Capdevila, Jaume |e verfasserin |4 aut | |
| 700 | 1 | |a García-Carbonero, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Grande, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Fonseca, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Marazuela, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Antona, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Aller, Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer treatment reviews |d 1993 |g 70(2018) vom: 15. Nov., Seite 209-222 |w (DE-627)NLM000409189 |x 1532-1967 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2018 |g day:15 |g month:11 |g pages:209-222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctrv.2018.09.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2018 |b 15 |c 11 |h 209-222 | ||